| Title |
Subjective perception versus objective outcome after intravitreal ranibizumab for exudative AMD
|
|---|---|
| Published in |
Graefe's Archive for Clinical and Experimental Ophthalmology, September 2011
|
| DOI | 10.1007/s00417-011-1792-8 |
| Pubmed ID | |
| Authors |
Konrad R. Koch, Philipp S. Muether, Manuel M. Hermann, Robert Hoerster, Bernd Kirchhof, Sascha Fauser |
| Abstract |
The efficacy of ranibizumab in preserving visual acuity in exudative age-related macular degeneration (AMD) has been widely demonstrated. However, statistically significant improvements in outcome measures such as best-corrected visual acuity (BCVA) may not necessarily be clinically relevant. Clinical relevance can be assumed when the treatment success is perceivable for the patient. We therefore investigated the relation between subjective perception of the treatment success and the objective outcome after intravitreal ranibizumab treatment. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 4% |
| Unknown | 23 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 17% |
| Other | 3 | 13% |
| Student > Ph. D. Student | 3 | 13% |
| Researcher | 3 | 13% |
| Student > Doctoral Student | 2 | 8% |
| Other | 6 | 25% |
| Unknown | 3 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 38% |
| Nursing and Health Professions | 4 | 17% |
| Agricultural and Biological Sciences | 2 | 8% |
| Neuroscience | 2 | 8% |
| Economics, Econometrics and Finance | 2 | 8% |
| Other | 3 | 13% |
| Unknown | 2 | 8% |